IL97900A - Substituted 5-(2- ( ( 2-aryl- 2-hydroxyethyl) amino) propyl)-1, 3-benzodioxoles and a process for producing them - Google Patents

Substituted 5-(2- ( ( 2-aryl- 2-hydroxyethyl) amino) propyl)-1, 3-benzodioxoles and a process for producing them

Info

Publication number
IL97900A
IL97900A IL97900A IL9790091A IL97900A IL 97900 A IL97900 A IL 97900A IL 97900 A IL97900 A IL 97900A IL 9790091 A IL9790091 A IL 9790091A IL 97900 A IL97900 A IL 97900A
Authority
IL
Israel
Prior art keywords
hydrogen
group
alkyl
benzodioxoles
hydroxyethyl
Prior art date
Application number
IL97900A
Other languages
English (en)
Other versions
IL97900A0 (en
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL97900A0 publication Critical patent/IL97900A0/xx
Publication of IL97900A publication Critical patent/IL97900A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL97900A 1990-05-04 1991-04-19 Substituted 5-(2- ( ( 2-aryl- 2-hydroxyethyl) amino) propyl)-1, 3-benzodioxoles and a process for producing them IL97900A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/519,192 US5061727A (en) 1990-05-04 1990-05-04 Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles

Publications (2)

Publication Number Publication Date
IL97900A0 IL97900A0 (en) 1992-06-21
IL97900A true IL97900A (en) 1997-04-15

Family

ID=24067267

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97900A IL97900A (en) 1990-05-04 1991-04-19 Substituted 5-(2- ( ( 2-aryl- 2-hydroxyethyl) amino) propyl)-1, 3-benzodioxoles and a process for producing them

Country Status (22)

Country Link
US (1) US5061727A (pl)
EP (1) EP0455006B1 (pl)
JP (1) JPH05320153A (pl)
KR (1) KR0181178B1 (pl)
CN (1) CN1037348C (pl)
AT (1) ATE181914T1 (pl)
AU (1) AU639094B2 (pl)
CA (1) CA2041712A1 (pl)
CZ (1) CZ283420B6 (pl)
DE (1) DE69131412D1 (pl)
DK (1) DK0455006T3 (pl)
ES (1) ES2133273T3 (pl)
FI (1) FI94862C (pl)
HU (2) HU210596B (pl)
IE (1) IE911509A1 (pl)
IL (1) IL97900A (pl)
NO (1) NO177822C (pl)
NZ (1) NZ237992A (pl)
PL (1) PL165665B1 (pl)
PT (1) PT97540B (pl)
SG (1) SG47917A1 (pl)
ZA (1) ZA913366B (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5245053A (en) * 1990-05-04 1993-09-14 American Cyanamid Company Substituted 5-(2-(2-aryl-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxoles
ES2174897T3 (es) * 1992-01-22 2002-11-16 Glaxo Group Ltd Uso medico de agonistas de beta-adrenoceptores atipicos.
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds
ATE163930T1 (de) * 1993-01-29 1998-03-15 American Cyanamid Co Aminocycloalkanobenzodioxole als beta-3 selektive adrenergische wirkstoffe
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5508461A (en) * 1993-06-04 1996-04-16 Daicel Chemical Industries, Ltd. Optically active 1-phenyl-2-substituted propane derivatives and methods of producing the same
WO1994029290A1 (en) * 1993-06-14 1994-12-22 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
JPH09502166A (ja) * 1993-07-31 1997-03-04 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アドレナリン受容体作動薬活性を有する２−ベンゾヘテロシクリルオキシまたはチオプロパノールアミン誘導体
US5578638A (en) * 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5563171A (en) * 1993-11-05 1996-10-08 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
EP0657439B1 (en) * 1993-12-09 1997-07-16 American Cyanamid Company Process improvement in the synthesis of [R-(R*,R*)]-5-(3-chlorophenyl)-3-(2-(3,4-dihydroxyphenyl)-1-methylethyl)-2-oxazolididone
US5420291A (en) * 1993-12-09 1995-05-30 American Cyanamid Company Process improvement in the synthesis of [R-(R*,R*)1-5-(3-chlorophenyl)-3-[2-]-2-oxazolidinone
US5438148A (en) * 1994-09-20 1995-08-01 American Cyanamid Company Process for the synthesis [R-(R*-,R*-)]-5-(3-chlorophenyl-3-[2-(3,4-dihydroxyphenyl)-1-methylethyl]-2
US5480908A (en) * 1993-12-13 1996-01-02 American Cyanamid Company β3 -adrenergic agents benzodioxole dicarboxylates and their use in pharmaceutical compositions
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5705515A (en) * 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5468865A (en) * 1994-05-03 1995-11-21 Celgene Corporation Stereopreferential synthesis of 3-(1-phenylprop-2-yl)-5-phenyloxazolidinones
US5461163A (en) * 1994-06-06 1995-10-24 American Cyanamid Company Synthesis and purification of [R-(R*,R*)]-5-[2-[5-(3-chloro-phenyl)-2-oxo-3-oxazolidinyl]-propyl]-1,-3-benzodiozole-2,2-dicarboxylic acid dimethyl ester
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5627200A (en) * 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
FR2732894B1 (fr) * 1995-04-13 1997-07-04 Sanofi Sa Nouvelle utilisation de composes agonistes beta9-adrenergiques
FR2734482B1 (fr) * 1995-04-13 1997-08-14 Sanofi Sa Nouvelle utilisation de composes agonistes beta3-adrenergiques
JP3068198B2 (ja) * 1995-05-12 2000-07-24 日清製粉株式会社 １，４−ベンゾジオキシン誘導体
US5597843A (en) * 1995-06-07 1997-01-28 Houghten Pharmaceuticals Use of a substituted 1,3-benzodioxole to reduce a wasting condition
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
CA2242351C (en) 1996-01-10 2003-03-11 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
EP0901484A1 (en) * 1996-05-14 1999-03-17 American Home Products Corporation Substituted 1, 3-benzodioxoles
US5914339A (en) * 1996-05-14 1999-06-22 American Home Products Corporation Substituted 1,3-benzodioxoles
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
DE69711519T2 (de) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
CA2271885A1 (en) * 1996-12-30 1998-07-09 American Home Products Corporation Substituted benzo[1,4]dioxanes as antiobesity agents
WO1999001431A1 (en) 1997-07-03 1999-01-14 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US6043253A (en) * 1998-03-03 2000-03-28 Merck & Co., Inc. Fused piperidine substituted arylsulfonamides as β3-agonists
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US20030220329A1 (en) * 1999-09-17 2003-11-27 Duke University Method of improving beta-adrenergic receptor function
WO2001044187A1 (en) * 1999-12-16 2001-06-21 Asahi Kasei Kabushiki Kaisha Novel substituted tricyclic compounds
KR100502876B1 (ko) 2000-04-28 2005-07-21 아사히 가세이 파마 가부시키가이샤 신규 이환성 화합물
JP2002053574A (ja) 2000-08-10 2002-02-19 Nisshin Pharma Inc １，４−ベンゾジオキサン環を有するプロパノールアミン誘導体
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7034053B2 (en) * 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
ES2309200T3 (es) 2001-10-25 2008-12-16 Asahi Kasei Pharma Corporation Compuesto biciclico.
AR057218A1 (es) 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
EP2351742A4 (en) 2008-10-09 2012-03-28 Asahi Kasei Pharma Corp indazole
WO2010041569A1 (ja) 2008-10-09 2010-04-15 旭化成ファーマ株式会社 インダゾール化合物
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
CA3230380A1 (en) 2021-09-01 2023-03-09 Nicholas MORRA Synthesis of mdma or its optically active (r)- or (s)-mdma isomers
EP4408832A4 (en) 2021-10-01 2025-10-29 Empathbio Inc NEW PRODICTIVES OF MDMA, MDA AND THEIR DERIVATIVES
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
JPS5310974B2 (pl) * 1974-06-10 1978-04-18
JPS51138638A (en) * 1975-05-12 1976-11-30 Smithkline Corp 33aminoo22substituteddphenyll11propanols
US4374149A (en) * 1977-06-03 1983-02-15 Sterling Drug Inc. α-{[(Arylalkyl)amino]alkyl}-4-hydroxy-3-(lower-alkylsulfinyl)benzenemethanols
US4490392A (en) * 1977-08-11 1984-12-25 Tanabe Seiyaku Co., Ltd. Benzylalcohol derivative and process for preparing
US4287205A (en) * 1978-06-20 1981-09-01 National Foundation For Cancer Research Hypotensive and analgesic compounds and compositions and methods for using same
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4751246A (en) * 1978-08-30 1988-06-14 Sterling Drug Inc. Compositions and method
US4452816A (en) * 1978-08-30 1984-06-05 Sterling Drug Inc. Method of lowering blood pressure by α-{[arylalkylamino]alkyl}-4-hydroxy-3-(loweralkylsulfinyl)benzenemethanols
JPS6010021B2 (ja) * 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
US4404222A (en) * 1980-08-25 1983-09-13 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby
DE3062216D1 (en) * 1979-09-06 1983-04-07 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
ATE14222T1 (de) * 1979-11-15 1985-07-15 Beecham Group Plc Sekundaere aethanolamine, ihre herstellung und ihre verwendung in pharmazeutischen zusammensetzungen.
DE3162756D1 (en) * 1980-05-22 1984-04-26 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
US4407819A (en) * 1980-08-25 1983-10-04 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for the depression of fat deposition in warm blooded animals
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
GB2096988B (en) * 1980-11-20 1984-08-01 Beecham Group Ltd Aromatic hydroxyamines
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers

Also Published As

Publication number Publication date
CA2041712A1 (en) 1991-11-05
HU211607A9 (en) 1995-12-28
PT97540B (pt) 1998-08-31
CN1037348C (zh) 1998-02-11
DK0455006T3 (da) 1999-11-22
CN1056495A (zh) 1991-11-27
FI912142A0 (fi) 1991-05-03
FI94862B (fi) 1995-07-31
HU210596B (en) 1995-05-29
EP0455006B1 (en) 1999-07-07
ATE181914T1 (de) 1999-07-15
CS9101285A2 (en) 1991-12-17
CZ283420B6 (cs) 1998-04-15
ES2133273T3 (es) 1999-09-16
PL165665B1 (pl) 1995-01-31
AU7607891A (en) 1991-11-07
NZ237992A (en) 1993-05-26
FI94862C (fi) 1995-11-10
IL97900A0 (en) 1992-06-21
IE911509A1 (en) 1991-11-06
JPH05320153A (ja) 1993-12-03
US5061727A (en) 1991-10-29
ZA913366B (en) 1992-03-25
PT97540A (pt) 1992-01-31
HU911495D0 (en) 1991-11-28
AU639094B2 (en) 1993-07-15
KR0181178B1 (ko) 1999-03-20
NO911751L (no) 1991-11-05
DE69131412D1 (de) 1999-08-12
NO177822C (no) 1995-11-29
KR910019999A (ko) 1991-12-19
PL290119A1 (en) 1992-07-27
NO177822B (no) 1995-08-21
FI912142L (fi) 1991-11-05
HUT59918A (en) 1992-07-28
EP0455006A3 (en) 1992-04-01
EP0455006A2 (en) 1991-11-06
NO911751D0 (no) 1991-05-03
SG47917A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
IL97900A (en) Substituted 5-(2- ( ( 2-aryl- 2-hydroxyethyl) amino) propyl)-1, 3-benzodioxoles and a process for producing them
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
HUT59669A (en) Process for producing n-sulfonyl-indoline derivatives and pharmaceutical compositions containing them
FR2741619B1 (fr) Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
IL79841A0 (en) Heterocyclic compounds,their production and pharmaceutical compositions containing them
HU9301048D0 (en) Acyl-amino-indole derivatives
CS327391A3 (en) Novel 3-cycloalkylpropaneamides, their tautomeric forms and their salts, process of their preparation and their application as medicaments and compositions containing said 3-cycloalkylpropaneamides
CA2152902A1 (fr) Ligands selectifs des recepteurs 5-ht1d-5ht1b derives d'indole-piperazine utiles comme medicaments
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
HUP0001165A2 (hu) NK1 és NK2 antagonista hatású acil-amino-alkil-amid-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra
FI834730A0 (fi) 1-karboxialkanoylperhydro-indol-2-karboxylsyror och deras derivat
DE69107217D1 (en) Oxysulfonylharnstoff-acat-inhibitoren.
HUT43787A (en) Process for production of medical compounds decreasing blood-pressure
ATE58135T1 (de) 1,3-oxathianderivate.
SE8901060D0 (sv) New compounds
MX9702028A (es) Antagonistas de bradiquinina heterociclicos, sustituidos con fluoroalquilo y fluoroalcoxi, procedimientos para su preparacion y su utilizacion.
DE69013461D1 (de) 1,3,4-Trisubstituierte Azetidin-2-on-Derivate, zur beta-Lactam-Synthese nützliche Zwischenprodukte und deren Verfahren zur asymmetrischen Herstellung.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees